Progressive Patterns of Giiftinib Treating Advanced Non-small Cell Lung Cancer after Obtained Resistance
10.3779/j.issn.1009-3419.2013.10.02
- VernacularTitle:吉非替尼治疗晚期非小细胞肺癌耐药后的进展模式分析
- Author:
WANG BIN
1
;
ZHANG XIN
;
LIN LIN
;
HAO XUEZHI
;
ZHANG XIANGRU
;
LI JUNLING
;
SHI YUANKAI
Author Information
1. 100021北京，中国医学科学院北京协和医学院肿瘤医院内科，抗肿瘤分子靶向药物临床研究北京市重点实验室
- Keywords:
Geiftinib;
Lung neoplsams;
Resistance;
Metastasis
- From:
Chinese Journal of Lung Cancer
2013;(10):510-513
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Clinical observation was conducted on the resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib (Iressa) therapy for advanced non-small cell lung cancer (NSCLC) patients. Methods Ninety-three NSCLC patients in our hospital, showing effective or stable condition after 6-month previous gefitinib therapy, were included in this investigation. Among the patients, 94.6%of them were suffering from adenocarcinoma. hTe percentage of female is 79.6%;the percentage of non-smoking is 80.6%. During the therapy period, follow-up was preformed every 2 months. Results Among the 93 patients, median therapy time was 16 months (range:8 to 70 months), and 21.5%(20/93) of them had received therapy for more than 2 years, while 8.6%(8/93) had received that for more than 3 years. hTe progression included 80%(72/90) for intrapleural progression, 38.9%(35/90) for primary tumor plus recurrence atfer sugary especially, 51.1%(46/90) for intrapulmonary metastasis, 25.6%(23/90) for pleural metastasis, 30%(30/90) for intracranial progression and 15.6%(14/90) for intraperitoneal progression. Conclusion Resistance to EGFR-TKI shows diversiifcation in clinical observation, therefore, close clinical follow-up is necessary for early attention and timely treatment.
